ELEV — Elevation Oncology Share News
0.000.00%
Last trade - 00:00Brief: Elevation Oncology Announces Promising Initial Data From Phase 1 Clinical Trial Evaluating EO-3021 In Patients With Advanced Unresectable Or Metastatic Solid Tumors Likely To Express Claudin 18.2
Elevation Oncology Inc expected to post a loss of 22 cents a share - Earnings Preview
Brief: Elevation Oncology Announces Planned Combination Strategy
Brief: Elevation Oncology Files For Mixed Shelf Of Upto $350 Million
Elevation Oncology Inc reports results for the quarter ended in December - Earnings Summary
U.S. RESEARCH ROUNDUP-Highpeak Energy, Nordstrom, Victoria'S Secret & Co
Brief: Elevation Oncology Appoints Julie Cherrington, Alan Sandler To Board
Brief: Elevation Oncology Expands Ongoing Phase 1 Clinical Trial Of EO-3021 Globally, Dosing First Patient In Japan
Brief: Elevation Oncology Regains Compliance With Nasdaq
Brief: Hannah E. Dunn Reports 7.3% Passive Stake In Elevation Oncology Inc As Of Jan 12, 2024 - SEC Filing
Brief: Elevation Oncology Announces Appointment Of Darcy Mootz, Ph.D., To Its Board Of Directors
Brief: Elevation Oncology Inc - Entering 2024 In Strong Financial Position, With Cash Into 2H 2025
Elevation Oncology Inc reports results for the quarter ended in September - Earnings Summary
Brief: Elevation Oncology Q3 basic EPS USD -0.25
Elevation Oncology Inc expected to post a loss of 32 cents a share - Earnings Preview
Advisory: Alert incorrectly tagged to Elevation Oncology withdrawn
Brief: Elevation Oncology - On Sept 19, Co Received Notice From Nasdaq That Co No Longer Complies With Minimum Bid Price Requirement For Continued Listing
Brief: Elevation Oncology Announces First Patient Dosed In The Phase 1 Clinical Trial Evaluating EO-3021
Brief: Elevation Oncology Reports Second Quarter 2023 Financial Results